Dr. Neumayer on Patient Education Following a Breast Cancer Diagnosis
Leigh A. Neumayer, MD, professor of surgery, University of Utah School of Medicine, co-director of the multidisciplinary team treating breast cancer at Huntsman Cancer Institute, discusses patient education following a breast cancer diagnosis.
Leigh A. Neumayer, MD, professor of surgery, University of Utah School of Medicine, co-director of the multidisciplinary team treating breast cancer at Huntsman Cancer Institute, discusses patient education following a breast cancer diagnosis.
Neumayer says that patients often have trouble absorbing information after receiving a cancer diagnosis. About five years ago, a nurse practioner had the idea for Neumayer to turn her initial 30-minute breast cancer educational talk into a video that patients could view at their leisure.​ After the video was made, Neumayer wanted to study how it helped patients with their levels of anxiety and knowledge.
The study enrolled 52 patients and has been completed, though data still needs to be analyzed. Anecdotally, Neumayer says that if a patient she sees in the clinic has viewed the video, she is able to have an exchange about that patient and their disease in particular.
Olaparib Plus Chemo May Not Improve Outcomes vs Chemo Alone in BRCA Wild-Type TNBC
April 23rd 2024Patients with BRCA wild-type triple-negative breast cancer treated with olaparib on a gap schedule with chemotherapy did not experience improved responses compared with chemotherapy alone in the neoadjuvant setting.
Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium
January 16th 2023Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.
FDA Grants Accelerated Approval to Fam-Trastuzumab Deruxtecan-Nxki in HER2+ Solid Tumors
April 5th 2024The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for patients with unresectable or metastatic HER2-positive solid tumors who have received prior systemic treatment.
